Eugenia Sacerdote de Lustig States to learn about the work of the professor Jonas Salk. When she returned to Argentina, she inoculated herself in public and did the same with her children to convince the population of the benefits of the polio vaccine. Since 1989, she investigated the role of free radicals and oxidative stress in living patients with Alzheimer's disease, vascular dementia and Parkinson's disease, expanding the basic knowledge of neurological diseases. Sacerdote de Lustig was a researcher at CONICET and head of virology at Instituto Malbrán. For more than 40 years, she studied tumor cells in the Instituto de Oncología Ángel H.
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood